Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
Crossref DOI link: https://doi.org/10.1007/s10549-017-4209-5
Published Online: 2017-03-21
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Matter-Walstra, K. https://orcid.org/0000-0002-5143-8112
Schwenkglenks, M.
Dedes, K. J.
License valid from 2017-03-21
